SPEF2: Key Regulator of Immune Response and Disease (G79925)

Target Name: SPEF2

NCBI ID: G79925

SPEF2

SPEF2: Key Regulator of Immune Response and Disease

SPEF2 (KPL2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the immune response and has been implicated in a number of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer.

SPEF2 is a member of the PPAR (peroxisome proliferator-activated receptor) family, which is a family of G protein-coupled receptors that play a role in cellular signaling. PPARs are characterized by a transmembrane domain, a short intracellular loop, and a unique N-terminal region that is rich in amino acids.

SPEF2 is expressed in a variety of tissues and is involved in a number of cellular processes, including immune response, inflammation, and metabolism. It is a negative regulator of the NF-kappa-B signaling pathway, which is a critical pathway involved in inflammation and stress responses.

SPEF2 has been shown to play a role in the regulation of immune cell function, including the activation and proliferation of natural killer (NK) cells. NK cells are a type of immune cell that play a critical role in fighting off infections and cancer. SPEF2 has been shown to regulate the expression of genes that are involved in the production of NK cells, as well as the activation and proliferation of NK cells.

SPEF2 has also been shown to play a role in the regulation of inflammation. Chronic inflammation is a major risk factor for a number of diseases, including heart disease, neurodegenerative disorders, and cancer. SPEF2 has been shown to regulate the production of pro-inflammatory cytokines, which are important drivers of chronic inflammation.

SPEF2 has also been shown to play a role in the regulation of metabolism. SPEF2 has been shown to regulate the production of glucose, which is an important source of energy for the body. It has also been shown to regulate the sensitivity of cells to insulin, which is important for maintaining normal blood sugar levels.

SPEF2 is also a potential drug target. Several studies have shown that SPEF2 is a promising drug target for a number of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. SPEF2 has been shown to interact with a variety of molecules, including transcription factors, cytokines, and enzymes involved in cellular signaling.

SPEF2 is also a potential biomarker for a number of diseases. The expression of SPEF2 has been shown to be altered in a variety of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. By studying the expression of SPEF2, researchers may be able to develop new diagnostic tests and therapies for these diseases.

In conclusion, SPEF2 is a protein that is involved in a variety of cellular processes and has been implicated in a number of diseases. Its unique structure and function make it an attractive target for research and development of new drugs and therapies. Further studies are needed to fully understand the role of SPEF2 in these diseases and to develop new treatments.

Protein Name: Sperm Flagellar 2

Functions: Required for correct axoneme development in spermatozoa. Important for normal development of the manchette and sperm head morphology. Essential for male fertility. Plays a role in localization of the intraflagellar transport protein IFT20 to the manchette, suggesting function as an adapter for dynein-mediated protein transport during spermatogenesis (PubMed:31278745, PubMed:31151990, PubMed:31048344). Also plays a role in bone growth where it seems to be required for normal osteoblast differentiation (By similarity)

The "SPEF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPEF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets